<DOC>
	<DOCNO>NCT00669942</DOCNO>
	<brief_summary>Evaluate safety , tolerability pharmacokinetics AIN457 administer single dose ( intravenous infusion ) patient active rheumatoid arthritis combination stable dose methotrexate . And compare efficacy dose group .</brief_summary>
	<brief_title>Double Blind , Placebo-controlled , Study Safety , Tolerability Pharmacokinetics AIN457 Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female patient active rheumatoid arthritis combination stable dose methotrexate age 1875 year may participate trial . Post menopausal surgically sterile female patient allow . Women childbearing potential may participate stable dose methotrexate practice effective contraception least 6 month prior screen , willing use 2 form contraception , include least 1 barrier method study least 2 month follow completion/discontinuation study . Patients must diagnosis active rheumatoid arthritis stage I , II III ( ACR 1987 revise classification criterion RA ) . Disease duration least 6 month prior randomization essential ; Current treatment antiTNFα anti IL1 therapy ( biological therapy ) . Patients congestive heart failure poorly control diabetes mellitus ( HbA1c value ≥10 % ) . Presence major chronic inflammatory autoimmune disease like psoriasis , psoriatic arthritis , spondyloarthropathy , inflammatory bowel disease SLE mimic rheumatoid arthritis diagnosis interfere efficacy evaluation study . History renal trauma , glomerulonephritis patient one kidney . Pregnant breastfeed woman exclude . A positive tuberculin skin test . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>